DongKoo Bio & Pharma Balance Sheet Health
Financial Health criteria checks 5/6
DongKoo Bio & Pharma has a total shareholder equity of ₩112.9B and total debt of ₩49.2B, which brings its debt-to-equity ratio to 43.6%. Its total assets and total liabilities are ₩210.6B and ₩97.6B respectively. DongKoo Bio & Pharma's EBIT is ₩16.4B making its interest coverage ratio 10.4. It has cash and short-term investments of ₩19.6B.
Key information
43.6%
Debt to equity ratio
₩49.21b
Debt
Interest coverage ratio | 10.4x |
Cash | ₩19.59b |
Equity | ₩112.92b |
Total liabilities | ₩97.64b |
Total assets | ₩210.56b |
Recent financial health updates
No updates
Financial Position Analysis
Short Term Liabilities: A006620's short term assets (₩89.6B) exceed its short term liabilities (₩87.8B).
Long Term Liabilities: A006620's short term assets (₩89.6B) exceed its long term liabilities (₩9.9B).
Debt to Equity History and Analysis
Debt Level: A006620's net debt to equity ratio (26.2%) is considered satisfactory.
Reducing Debt: A006620's debt to equity ratio has increased from 30.4% to 43.6% over the past 5 years.
Debt Coverage: A006620's debt is well covered by operating cash flow (23.2%).
Interest Coverage: A006620's interest payments on its debt are well covered by EBIT (10.4x coverage).